Lightnews — Scholar-powered news

Reposted by Mahdad Noursadeghi

yEFIS @yefis-immunology.bsky.social · Aug 25

👶✈️ Balancing caregiving and academic travel?

Join Dr. Laura Pallett for "The Dual Demands of Academic Travel and Caregiving"

🗓️ Sept 25 | 🕒15:00 CEST
🔗https://tinyurl.com/yefis2025-ia2

Hosted by the Improving Academia group of yEFIS

1 10 9

Reposted by Mahdad Noursadeghi

Gabriele Pollara @gpollara.bsky.social · May 31

In @elife.bsky.social: Type I interferon responses contribute to immune protection against mycobacterial infection doi.org/10.7554/eLif...
#TBSky #IDSky #Immunosky
work led by Gillian Tomlinson with support from @mnoursad.bsky.social & @innate2adaptive.bsky.social group (1/5)

Type I interferon responses contribute to immune protection against mycobacterial infection

doi.org

1 4 9

Reposted by Mahdad Noursadeghi

Tom Samuels @thomashasamuels.bsky.social · Apr 30

Very excited to share our new piece of work in the Lancet Global Health @lancetgh.bsky.social – Periskope-CM, a set of personalised risk prediction tools for HIV-associated cryptococcal meningitis mortality: www.thelancet.com/journals/lan...
#IDsky #HIV #GlobalHealth #meningitis #fungal
1/8

Lancet

www.thelancet.com

1 2 3

Reposted by Mahdad Noursadeghi

Gabriele Pollara @gpollara.bsky.social · Apr 30

Come on down, anyone eligible for a post-doc do consider applying for this exciting project with @jennyrohn.bsky.social, @scottishwormboy.bsky.social & me!

Got a touch of #UTISky #IDSky #ImmunoSky & 🧪 about it! 😉

Prof Jenny Rohn @jennyrohn.bsky.social · Apr 30

*JOB ADVERT LIVE!* Come be my next MRC-funded postdoc in London, studying uropathogenic E. coli virulence/host response in our lovely human urothelial microtissue model! Great collaboration with @gpollara.bsky.social & @scottishwormboy.bsky.social #UTISky #UTI Join us! www.ucl.ac.uk/work-at-ucl/...

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

www.ucl.ac.uk

6 5

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

We also hope Metaclonotypist will prove to be a valuable application for fast and flexible parameter optimisation for identification of T cell metaclones across wide-ranging disease domains.

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

Given the critical role of T cell immunity in TB, we are excited about the potential for using generalisable T cell metaclones for improved disease-risk stratification in Mtb-infected people, and for identification of T cell epitopes for development of more effective vaccines.

1

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

Although the predominant repertoire of T cell reactivity to Mtb epitopes is private to individuals, we found striking evidence for population-wide immunodominance at the level of individual pMHC specificity revealed by highly generalisable/public T cell metaclones.

1

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

To overcome inter-individual TCR sequence diversity for shared peptide-MHC specific responses to Mtb , we developed a new computational pipeline, Metaclonotypist, to identify HLA-associated clusters of similar TCR sequences (metaclones) across a large ethnically diverse study population.

1

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

We used the tuberculin skin test as a standardised in vivo challenge comprising the whole Mtb proteome to generate localised enrichment of Mtb reactive T cells derived from the whole in vivo repertoire, which we characterised by TCR sequencing.

1

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 21

Interested in T cell immunity in TB? Check out our new pre-print on antigen-agnostic identification of generalisable human in vivo Mtb-reactive T cell responses: www.biorxiv.org/content/10.1...
with @qimmuno.bsky.social & @innate2adaptive.bsky.social

Evolution of T cell responses in the tuberculin skin test reveals generalisable Mtb-reactive T cell metaclones.

T cells contribute to immune protection and pathogenesis in tuberculosis, but measurements of polyclonal responses have failed to resolve correlates of outcome. We report the first temporal…

www.biorxiv.org

1 8 13

Reposted by Mahdad Noursadeghi

satviuct.bsky.social @satviuct.bsky.social · Apr 15

Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow selection of most promising TB vaccine candidates. This work is supported by the South African mRNA Vaccine Consortium & funded by @samrcza.bsky.social @tomscriba.bsky.social www.youtube.com/watch?v=zwPM...

1 3 4

Reposted by Mahdad Noursadeghi

satviuct.bsky.social @satviuct.bsky.social · Apr 15

Immunopathology of TB: SATVI researchers discuss a groundbreaking study which investigates the role of lymph nodes in the context of mycobacterium tuberculosis infection and disease. The study was funded by a grant from
@wellcomeleap.bsky.social a program of youtu.be/8_gCOAfWUpw

Immunopathology of TB: Studying the role of the lymph nodes in the TB spectrum.

YouTube video by SATVIUCT

youtu.be

2 2

Mahdad Noursadeghi @mnoursad.bsky.social · Apr 11

2 weeks to the deadline for applications to this post.. take a look, get in touch if you want hear more, don't hold back😎

Mahdad Noursadeghi @mnoursad.bsky.social · Mar 27

We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu

5 3

Reposted by Mahdad Noursadeghi

T cell Vaccines Lab (Swadling UCL) 🧬👩🏽‍🔬 @tcellvaccineucl.bsky.social · Mar 28

It's just under 1 month to World Immunisation Week 2025 (24th - 30th April)! Check the link below to read more about this crucial campaign for global health.

www.who.int/campaigns/wo...

#WorldImmunisationWeek #VaccinesWork #WHO

World Immunization Week 2025

World Immunization Week, celebrated in the last week of April, aims to promote the life-saving power of immunization to protect people of all ages against vaccine-preventable diseases. Vaccines are on...

www.who.int

1 2

Reposted by Mahdad Noursadeghi

Michael Marks @drmichaelmarks.bsky.social · Mar 28

Academic Clinical Lecturer Posts in Infection now out: for people training in ID in UK & hold/imminently completing PhD.

2 posts @lshtm.bsky.social
shorturl.at/EIUIz

1 at St Georges & 1 at Kings
shorturl.at/8kDY3

If interested in @lshtm.bsky.social posts get in touch.
UK ID people please share!!

12 6

Mahdad Noursadeghi @mnoursad.bsky.social · Mar 27

We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu

13 9

Mahdad Noursadeghi @mnoursad.bsky.social · Feb 21

This is a great initiative!

Georgia Walton @drgeorgiawalton.bsky.social · Feb 21

I am beyond excited to share that you can now apply to observe a @wellcometrust.bsky.social #DiscoveryResearch shortlisting Committee! If you plan to apply to us in the next 2 years, apply to be an Observer now to better understand what happens once you click submit! wellcome.org/grant-fundin...

Apply to observe a Wellcome funding advisory committee | Prepare to Apply | Wellcome

Find out how to observe a Wellcome funding advisory committee. Researchers who are considering applying for Wellcome funding in the next two years can apply to observe a shortlisting committee.

wellcome.org

1 2

Mahdad Noursadeghi @mnoursad.bsky.social · Jan 10

Fab analysis @hannahrickman.bsky.social - will we be well cited. are there sex-stratified data for house-hold contacts for which we may expect similar exposures?

1 1 2

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 14

State of the art in the enigmatic and complex world of immunological determinants of TB👇

Tom Scriba @tomscriba.bsky.social · Dec 13

Interested in the immunopathology of human tuberculosis? Here is our latest review:
www.science.org/doi/10.1126/...

Immunopathology in human tuberculosis

The balance between protective and pathological immune responses shapes progression of Mycobacterium tuberculosis infection.

www.science.org

1

Reposted by Mahdad Noursadeghi

Kat Mayer-Barber,PhD @mayerbarber.bsky.social · Dec 6

Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9

Graphical summary of our paper. In mice, prior lower airway exposure to diverse inflammatory stimuli, including chronic bacterial infections such as M. tuberculosis, acute bacterial infections such as pulmonary S. aureus, viral infections such as Influenza A, type-II allergic responses such as the OVA-Alum model, activation of pulmonary TLR9 by CpG or pulmonary TLR1/2 by Pam3CSK4
leads to reduced viral burden upon subsequent infection with SARS-CoV-2 (SCV2). (2) This SCV2 restriction occurs prior to induction of SCV2-specific adaptive immune responses
and is mediated through innate immune responses, including the induction of IFN-I, TNFα and IL-1 and sustained changes to the TRM (Tissue resident macrophage) cellular
compartment and the pulmonary epithelium. (3) Innate cytokine and TLR signaling to both recruited immune cells and the pulmonary epithelium creates a microenvironment in the
lung that limits early replication of SCV2. IFN-I signaling to pulmonary ECs (epithelial cells) increases expression of interferon-stimulated genes, that likely cell-intrinsically limit viral
replication. TNF- or IL-1 suppress SCV2 independently of IFN-I signaling. TNF acts exclusively through radio-resistant cell types such as the lung epithelium, whereas IL-1 affords
control both direct and indirectly, through either stromal and hematopoietic cell types, to restrict overall early SCV2 burden.

28 83 300

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 4

Exciting- live to hear more!

1

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 3

important point- have not done this yet- wonder whether protein as dynamic as transcripts

1

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 2

and these data from unselected acute respiratory viruses in community acquired infection - with longitudinal sampling after the symptom onset

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 2

Not sure if I have misunderstood- our findings that distinct biomarkers discriminate early & late phases of infection were generalisable to all acute respiratory viruses we have been able to test - panel on right = extended time course from Flu challenge

1

Mahdad Noursadeghi @mnoursad.bsky.social · Dec 2

Obviously super important consideration -debated extensively - for interest, some more commentary and reflections here: www.nejm.org/doi/10.1056/...

SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic | NEJM

While commentators have made theoretical arguments for and against SARS-CoV-2 challenge studies, a consortium of academics, industry collaborators, and the British government has proceeded to addre...

www.nejm.org

1